Programme - Developing new dialogue

Session I
	From Science to Society Lewis Wolpert, Professor of Biology as Applied to Medicine, University College London, UK
	Case studies A retrospective on specific issues where the checks and balances that are in place have worked and/or failed
	From Pan to pandemic: HIV and AIDS Robin Weiss, University College London, UK
	The Saga of BSE John Collinge, Imperial College, London, UK
	Risk studies Theory and practice
	Why framing processes in risk science are important: but still neglected Brian Wynne, Lancaster University, UK
	Framing public perceptions of risk: agricultural GMOs in Europe Claire Marris, University of Versailles, France
	Panel discussion: how to restore public trust in science Maynard Olson (Chair), University of Washington, USA Beate Weber, Lady Major of Heidelberg, Germany Tom Wilkie, Wellcome Trust, UK Julian Kinderlerer , Sheffield University, UK Orla Smith, Science, USA Maurizio Iaccarino, International Institute of Genetics and Biophysics, Italy

Session II
	Medical uses of genetic information: gene therapy, prenatal diagnostics, and population genetics Jens Reich (Chair), Max-delbrück-Centrum, Germany
	From the sequence of our genes to medical utility Andrea Ballabio, TIGEM, Italy
	The social costs of better disease treatments Peter Goodfellow, Smith-Kline Beecham Pharmaceuticals, UK
	Genetic research and common diseases Kari StefÃ¡nsson, deCode Genetics, Iceland

Session III
	On human genome projects: uses and abuses John Collinge (Chair), Imperial College London, UK
	The genomic turn: is the genome the new name of the soul? Alexandre Mauron, University of Geneva
	Debating human identity: institutional commitments and consequences Sheila Jasanoff, Harvard University, USA
	The human genome project: a scientist's view of what went right and what went wrong Maynard Olson, University of Washington, USA
	Past and future of behavioural genetics Benno Müller-Hill, University of Cologne, Germany
	Panel discussion: public understanding of genetic information Alastair Kent (Chair), Genetic Interest Group, UK Barbara Cohen, Ludwig Institute of Cancer Research, USA Jean Louis Mandel, IGBMC, France Alexandre Mauron, University of Geneva, Switzerland Vivienne Parry, BBC, UK
	Presentation of GEOD journalism award for Human Genetics

Session IV
	Biotechnology, bio-industry, bio-business Charles Kurland (Co-Chair), BMC, Sweden and Chris Leaver (Co-Chair), Oxford University, UK
	Business with biotech: Europe vs. USA reality vs. wishful thinking Friedrich von Bohlen, lion Bioscience AG, Germany
	Biotechnology at the beginning of the third millennium: facts and global trends Manfred Kern, Aventis, Germany
	Antibiotics for the 21st century Julian Davies, University of British Colombia, Canada
	Defending animal use in biotechnology Alan Colman, PPL Therapeutics
	Panel discussion: biotechnology and its discontents Julian Kinderlerer (Chair), Sheffield University, UK Hans-Jürg Rheinberger, MPI History of Science, Germany Mark Cantley, European Commission, Belgium Sheila Jasanoff, Harvard University, USA Stefan Flothmann, Greenpeace, Germany David Dickson, Nature, UK
	Science in the spotlight Julian Kinderlerer (Chair), Sheffield University, UK
	Science in theater: an historical account Ivo Schneider, Bundeswehr UniversitÃ¤t, Munich, Germany
	Science in theater Carl Djerassi, Stanford University, USA